Renal events in patients receiving neprilysin inhibitors : a systematic review and meta-analysis
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA..
BACKGROUND: While it is well known that angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) increase the risk of acute renal failure, the role of neprilysin inhibition (NEPi) is unclear and some physicians are reluctant to prescribe sacubitril/valsartan because of safety concerns. This meta-analysis aimed to examine the risk for renal events, progression of chronic kidney disease (CKD) or progression to dialysis on combined NEPi and ACEi/ARBs compared with ACEi or ARBs.
METHODS: We performed a systematic meta-analysis including 17 randomized controlled trials (study drug sacubitril/valsartan or omapatrilat), involving a total of 23 569 patients, after searching PubMed, Cochrane, ClinicalTrials.org and Embase for eligible studies. From the included trials, all renal endpoints, including long- and short-term outcomes and hyperkalemia, were extracted. Pooled odds ratios (ORs) were calculated using the DerSimonian and Laird method. The study was registered at PROSPERO.
RESULTS: Overall, treatment with sacubitril/valsartan or omapatrilat showed a slightly lower risk of any renal event [OR 0.82 (0.7-0.97)] compared with treatment with an ACEi or ARB alone. Also, there was a decreased risk of severe acute renal events [OR 0.8 (0.69-0.93)] and a decrease in estimated glomerular filtration rate decline [mean difference -0.58 mL/min (-0.83 to -0.33 mL/min)]. There was no difference in chronic renal events [OR 0.92 (0.8-1.05)] or hyperkalemia [OR 1.02 (0.84-1.23)].
CONCLUSION: NEPi + ACEi/ARBs are safe in terms of renal adverse events. Longer trials focusing on CKD are needed to evaluate the effect of NEPi on decreasing progression of CKD.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
---|---|
Enthalten in: |
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 37(2022), 12 vom: 23. Nov., Seite 2418-2428 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Vollmer Barbosa, Clara [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 24.11.2022 Date Revised 29.12.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/ndt/gfac001 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335576486 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335576486 | ||
003 | DE-627 | ||
005 | 20231225230149.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/ndt/gfac001 |2 doi | |
028 | 5 | 2 | |a pubmed24n1118.xml |
035 | |a (DE-627)NLM335576486 | ||
035 | |a (NLM)35022763 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Vollmer Barbosa, Clara |e verfasserin |4 aut | |
245 | 1 | 0 | |a Renal events in patients receiving neprilysin inhibitors |b a systematic review and meta-analysis |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.11.2022 | ||
500 | |a Date Revised 29.12.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. | ||
520 | |a BACKGROUND: While it is well known that angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs) increase the risk of acute renal failure, the role of neprilysin inhibition (NEPi) is unclear and some physicians are reluctant to prescribe sacubitril/valsartan because of safety concerns. This meta-analysis aimed to examine the risk for renal events, progression of chronic kidney disease (CKD) or progression to dialysis on combined NEPi and ACEi/ARBs compared with ACEi or ARBs | ||
520 | |a METHODS: We performed a systematic meta-analysis including 17 randomized controlled trials (study drug sacubitril/valsartan or omapatrilat), involving a total of 23 569 patients, after searching PubMed, Cochrane, ClinicalTrials.org and Embase for eligible studies. From the included trials, all renal endpoints, including long- and short-term outcomes and hyperkalemia, were extracted. Pooled odds ratios (ORs) were calculated using the DerSimonian and Laird method. The study was registered at PROSPERO | ||
520 | |a RESULTS: Overall, treatment with sacubitril/valsartan or omapatrilat showed a slightly lower risk of any renal event [OR 0.82 (0.7-0.97)] compared with treatment with an ACEi or ARB alone. Also, there was a decreased risk of severe acute renal events [OR 0.8 (0.69-0.93)] and a decrease in estimated glomerular filtration rate decline [mean difference -0.58 mL/min (-0.83 to -0.33 mL/min)]. There was no difference in chronic renal events [OR 0.92 (0.8-1.05)] or hyperkalemia [OR 1.02 (0.84-1.23)] | ||
520 | |a CONCLUSION: NEPi + ACEi/ARBs are safe in terms of renal adverse events. Longer trials focusing on CKD are needed to evaluate the effect of NEPi on decreasing progression of CKD | ||
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Journal Article | |
650 | 4 | |a neprilysin inhibitor | |
650 | 4 | |a renal events | |
650 | 4 | |a sacubitril | |
650 | 7 | |a sacubitril |2 NLM | |
650 | 7 | |a 17ERJ0MKGI |2 NLM | |
650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
650 | 7 | |a omapatrilat |2 NLM | |
650 | 7 | |a 36NLI90E7T |2 NLM | |
650 | 7 | |a Neprilysin |2 NLM | |
650 | 7 | |a EC 3.4.24.11 |2 NLM | |
650 | 7 | |a Valsartan |2 NLM | |
650 | 7 | |a 80M03YXJ7I |2 NLM | |
700 | 1 | |a Lang, Hannah |e verfasserin |4 aut | |
700 | 1 | |a Melk, Anette |e verfasserin |4 aut | |
700 | 1 | |a Schmidt, Bernhard M W |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |d 1990 |g 37(2022), 12 vom: 23. Nov., Seite 2418-2428 |w (DE-627)NLM012639206 |x 1460-2385 |7 nnns |
773 | 1 | 8 | |g volume:37 |g year:2022 |g number:12 |g day:23 |g month:11 |g pages:2418-2428 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/ndt/gfac001 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 37 |j 2022 |e 12 |b 23 |c 11 |h 2418-2428 |